43 results on '"Pandit-Abid, Nami"'
Search Results
2. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
3. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma
4. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
5. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps
6. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
7. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype
8. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
9. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies
10. Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
11. Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma.
12. Impact of dupilumab across seasons in patients with type 2 uncontrolled, moderate-to-severe asthma
13. BASELINE CHARACTERISTICS OF PATIENTS WITH ASTHMA AND PRIOR SYSTEMIC CORTICOSTEROID USE INITIATING DUPILUMAB IN REAL-WORLD CLINICAL PRACTICE IN THE RAPID REGISTRY
14. Baseline characteristics of patients with asthma and prior systemic corticosteroid use in the RAPID (dupilumab) registry
15. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
16. Dupilumab Improves Long‐term Outcomes in Patients With Uncontrolled, Moderate‐to‐Severe GINA‐Based Type 2 Asthma, Irrespective of Allergic Status
17. Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
18. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
19. Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose.
20. Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose.
21. Dupilumab Reduces Exacerbations And Improves Lung Function Regardless Of Prior Asthma Exacerbation Status: LIBERTY ASTHMA TRAVERSE Open-Label Extension Study
22. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose
23. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
24. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
25. DUPILUMAB TREATMENT LEADS TO SUSTAINED REDUCTIONS IN ORAL CORTICOSTEROID USE IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA
26. STOP GOES MY HEART: PERMANENT PACEMAKER IMPLANTATION FOR BRASH SYNDROME-RELATED COMPLETE HEART BLOCK
27. DUPILUMAB REDUCED EXACERBATIONS AND IMPROVED LUNG FUNCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA AND PRIOR EXACERBATIONS: LIBERTY ASTHMA TRAVERSE STUDY
28. Long-term efficacy of dupilumab in asthma with and without chronic rhinosinusitis and/or nasal polyps.
29. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma.
30. Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST
31. Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE
32. Effect of dupilumab on improving physical activity in patients with severe asthma
33. Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients
34. Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
35. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
36. Prevalence of Allergy and Type 2 Inflammatory Comorbidities in Adolescents With Uncontrolled, Moderate-to-Severe Asthma
37. DUPILUMAB REDUCES SEVERE OUTPATIENT ASTHMA EXACERBATIONS, CUMULATIVE DOSE, AND TOTAL NUMBER OF DAYS OF SYSTEMIC CORTICOSTEROID USE AMONG PATIENTS WITH MODERATE-TO-SEVERE TYPE-2 ASTHMA
38. DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA
39. DUPILUMAB IMPROVES LUNG FUNCTION IN PATIENTS IRRESPECTIVE OF ON-STUDY ASTHMA EXACERBATIONS
40. Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study
41. Effect of Dupilumab on patient-reported breathing and rescue medication use
42. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma
43. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.